Eversept Partners’s Aerie Pharmaceuticals AERI Stock Holding History

Eversept Partners’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-256,289	Closed	-$3.88M	–	84
2022 Q3	$3.88M	Buy	+256,289	New	+$2.98M	0.34%	41
2019 Q2	–	Sell	-114,779	Closed	-$5.45M	–	72
2019 Q1	$5.45M	Sell	114,779 -118,011	-51%	-$5.19M	1.59%	18
2018 Q4	$8.4M	Buy	232,790 +112,079	+93%	+$5.26M	4.55%	7
2018 Q3	$7.43M	Sell	120,711 -106,191	-47%	-$6.83M	3.26%	11
2018 Q2	$15.3M	Buy	226,902 +16,124	+8%	+$902K	7.01%	3
2018 Q1	$11.4M	Sell	210,778 -30,702	-13%	-$1.72M	5.31%	5
2017 Q4	$14.4M	Buy	+241,480	New	+$14.6M	8.3%	3

Eversept Partners's AERI Position: Q4 2022 in Review

Eversept Partners sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 256,289 shares — an estimated $3.88M sold.

Eversept Partners first reported a position in AERI in Q4 2017 and held it in 7 quarters. The position peaked at $15.3M in Q2 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Eversept Partners reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Eversept Partners sold 256,289 Aerie Pharmaceuticals shares in Q4 2022, an estimated $3.88M.
Eversept Partners first reported a position in Aerie Pharmaceuticals in Q4 2017 and held it in 7 quarters.
Eversept Partners's Aerie Pharmaceuticals position peaked at $15.3M in Q2 2018.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Eversept Partners's 13F filing for Q4 2022, filed 14 Feb 2023.